MedTrace Logo

A Prospective Study on Optimizing Treatment for ABPA

NCT05129033 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2021-11-22

No results posted yet for this study

Summary

This study is being done to evaluate the efficacy of treatment using oral glucocorticoid, anti-fungal agent, anti-IgE mAb for patient with ABPA.

Conditions

  • Allergic Bronchopulmonary Aspergillosis

Interventions

DRUG

Prednisone tablet

Basic medication for allergic airway inflammation such as asthma and ABPA, to relieve inflammation. Reduction may failed if disease exacerbate.

DRUG

itraconazole

Anti-fungal medication to reduce fugal load.

BIOLOGICAL

Omalizumab

Anti-IgE monoclonal antibody, used for high IgE allergic disease.

Sponsors & Collaborators

  • Shanghai Zhongshan Hospital

    lead OTHER

Principal Investigators

  • Meiling Jin, MD · Department of Respiratory, Zhongshan Hospital, Fudan University Shanghai, China

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-11-15
Primary Completion
2023-06-30
Completion
2023-12-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05129033 on ClinicalTrials.gov